MAIA Biotechnology (MAIA) Q2 2024 earnings summary

Executive summary

• MAIA Biotechnology is a clinical-stage biotech focused on cancer therapies, with lead asset THIO in Phase 2 trials for NSCLC and multiple recent clinical and regulatory milestones, including orphan drug designations and positive interim efficacy data.

• The company completed enrollment in its Phase 2 THIO-101 trial, reported strong disease control and response rates, and continues to expand its clinical pipeline and intellectual property portfolio.

• Multiple private placements and at-the-market offerings raised over $12M year-to-date, supporting ongoing R&D and operations.

Financial highlights

• Cash and cash equivalents were $11.6M as of June 30, 2024, up from $7.2M at December 31, 2023.

• Net loss for Q2 2024 was $8.9M, compared to $4.5M in Q2 2023; net loss for the six months ended June 30, 2024 was $16.9M, up from $8.6M year-over-year.

• Operating expenses for Q2 2024 decreased 18% year-over-year to $3.8M, driven by lower payroll and stock-based compensation, partially offset by higher clinical research costs.

• Other expense, net, increased significantly due to a $5.3M change in fair value of warrant liabilities in Q2 2024.

Outlook and guidance

• The company expects to continue incurring losses and negative cash flows as it advances clinical trials and lacks revenue-generating activities.

• Management indicates substantial doubt about the ability to continue as a going concern within one year without additional capital raises.

• Plans to fund operations through further equity or debt financings, with no assurance of availability or terms.